Literature DB >> 21122505

Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection.

Shomron Ben-Horin1, Maya Margalit, Peter Bossuyt, Jochen Maul, Yami Shapira, Daniela Bojic, Irit Chermesh, Ahmad Al-Rifai, Alain Schoepfer, Matteo Bosani, Matthieu Allez, Peter Laszlo Lakatos, Fabrizio Bossa, Alexander Eser, Tommaso Stefanelli, Franck Carbonnel, Konstantinos Katsanos, Davide Checchin, Inés Sáenz de Miera, Walter Reinisch, Yehuda Chowers, Gordon William Moran.   

Abstract

BACKGROUND AND AIM: Limited data suggests that pseudomembranes are uncommon in patients with inflammatory bowel disease (IBD) and C. difficile associated disease (CDAD), but the reason for this is unknown. We aimed to evaluate the rate of pseudomembranes in this population, identify predictive factors for pseudomembranes' presence and assess its clinical impact.
METHODS: This was a sub-study of a retrospective European Crohn's & Colitis Organization (ECCO) multi-center study on the outcome of hospitalized IBD patients with C. difficile. The present study included only patients who underwent lower endoscopy during hospitalization, and compared demographic and clinical parameters in the group of patients with discernable pseudomembranes versus those without.
RESULTS: Out of 155 patients in the original cohort, 93 patients underwent lower endoscopy and constituted the study population. Endoscopic pseudomembranes were found in 12 (13%) of these patients. Patients with pseudomembranes presented more commonly with fever (p=0.02) compared to patients without pseudomembranes. No difference between the two groups was found with respect to the use of immunosuppressant drugs, background demographics or disease characteristics. Neither was there a difference between the group with or without pseudomembranes in the frequency of severe adverse clinical outcome or in the duration of hospitalization. On multi-variate analysis the presence of fever remained independently associated with the finding of pseudomembranes (OR 6, 95% CI 1.2-32, p=0.03).
CONCLUSIONS: This study documents that hospitalized IBD patients with CDAD have low rate of endoscopic pseudomembranes, which is not accounted for by the use of immunosuppressant drugs. IBD patients with CDAD and discernable pseudomembranes more commonly present with fever, but their clinical outcome is similar to patients without pseudomembranes.
Copyright © 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 21122505     DOI: 10.1016/j.crohns.2009.11.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  24 in total

1.  Strategies for management of Clostridium difficile infection in immunosuppressed patients.

Authors:  David G Binion
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.

Authors:  Krista M Newman; Kevin M Rank; Byron P Vaughn; Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-01-19

3.  [Diagnostic options. Indications and validity].

Authors:  A Stallmach; M Bürger; M Weber
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

Review 4.  Clostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment.

Authors:  Ying M Tang; Christian D Stone
Journal:  Clin J Gastroenterol       Date:  2017-02-16

Review 5.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

6.  Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab.

Authors:  Andrada Seicean; Anca Moldovan-Pop; Radu Seicean
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 7.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

Review 8.  Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Nancy Fu; Titus Wong
Journal:  Curr Infect Dis Rep       Date:  2016-06       Impact factor: 3.725

9.  The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease.

Authors:  T Berdichevski; N Keller; G Rahav; S Bar-Meir; R Eliakim; S Ben-Horin
Journal:  Infection       Date:  2013-05-26       Impact factor: 3.553

Review 10.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.